异丙托溴铵和沙美特罗/替卡松联合吸入治疗慢性阻塞性肺疾病稳定期疗效观察  

Therapeutic effect of ipratropium bromide and salmeterol/ticasone in the treatment of chronic obstructive pulmonary disease in the stable period

作　　者：郑稳 江瑞来 ZHENG Wen;JIANG Ruilai(Department of Respiratory and Critical Care Medicine,Lishui Second People's Hospital in Zhejiang Province,Lishui323000,China)

机构地区：[1]浙江省丽水市第二人民医院呼吸及重症医学科

出　　处：《中国现代医生》2019年第32期89-92,共4页China Modern Doctor

基　　金：浙江省医药卫生科技计划项目（2019KY809）

摘　　要：目的探讨异丙托溴铵和沙美特罗/替卡松联合吸入治疗慢性阻塞性肺疾病稳定期的临床疗效。方法选取2018年1月~2019年1月我院住院的慢性阻塞性肺疾病患者60例,随机分为观察组与对照组,各30例,两组患者均给予戒烟、家庭氧疗、呼吸训练等常规治疗,对照组给予舒利迭(沙美特罗/替卡松),观察组联合采用异丙托溴铵。两组均治疗1周后,进行疗效、临床症状体征评分及肺功能、生活质量改善情况比较。结果观察组与对照组患者治疗后显效率分别为60.00%、30.00%,两组无效率分别为6.67%、30.00%,两组患者治疗后的总有效率分别为93.33%、70.00%,组间比较差异具有显著性(P<0.05)。观察组与对照组患者治疗后症状体征评分率分别为(3.56±0.17)分、(5.31±0.45)分,生活质量SGRQ评分分别为(42.86±8.19)分,(47.21±71.34)分,与治疗前比较均显著降低,两组治疗后的症状体征评分组间比较,差异有显著性(P<0.05)。治疗前两组患者的FVC、FEV1/预计值、FEV1/FVC及MVV比较,差异无显著性(P>0.05)。治疗后1,3个月,两组患者的FVC、FEV1/预计值、FEV1/FVC及MVV水平分别与治疗前比较均明显升高,且治疗组患者治疗后1个月,3个月的FVC、FEV1/预计值、FEV1/FVC及MVV水平分别显著高于对照组,两组比较差异有显著性(P>0.05)。结论异丙托溴铵和沙美特罗/替卡松联合吸入治疗慢性阻塞性肺疾病稳定期能够提高临床疗效,缓解临床症状,提高肺功能及生活质量,值得广泛推广和应用。Objective To observe the clinical efficacy of ipratropium bromide and salmeterol/ticasone in the treatment of chronic obstructive pulmonary disease in the stable period. Methods 60 patients with chronic obstructive pulmonary disease admitted to our hospital from January 2018 to January 2019 were randomly divided into observation group and control group, with 30 cases in each group. Both groups were given smoking cessation, family oxygen therapy, respiratory training treatment. The control group was given sullidide(salmeterol/ticasone), and the observation group was combined with ipratropium bromide. After 1 week of treatment, the efficacy, clinical symptoms and signs, lung function and quality of life improvement were compared. Results The effective rates of the observation group and the control group were 60.00% and 30.00%, respectively. The ineffective rates of the two groups were 6.67% and 30.00%, respectively.The total effective rate after treatment of the two groups was 93.33% and 70.00%, respectively. The difference between the two groups was significant(P<0.05). The scores of symptoms and signs after treatment in the observation group and the control group were(3.56±0.17) points,(5.31±0.45) points, and the quality of life SGRQ score was(42.86±8.19) points and(47.21±11.34) points, which were significantly lower than those before treatment. There was a significant difference in symptom scores between the two groups after treatment(P<0.05). There were no significant differences in FVC, FEV1/predicted values, FEV1/FVC and MVV between the two groups before treatment(P>0.05). At 1 and 3 months after treatment, the FVC, FEV1/predicted value, FEV1/FVC and MVV levels in the two groups were significantly higher than those before treatment. And the FVC, FEV1/predicted value, FEV1/FVC and MVV levels in the observation group were significantly higher than those of the control group at 1 month and 3 months after treatment, and the difference between the two groups was significant(P>0.05). Conclusion The combination

关 键 词：慢性阻塞性肺疾病稳定期 异丙托溴铵 沙美特罗/替卡松 生活质量 

分 类 号：R563.9[医药卫生—呼吸系统]